<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="191434">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600600</url>
  </required_header>
  <id_info>
    <org_study_id>660</org_study_id>
    <nct_id>NCT00600600</nct_id>
  </id_info>
  <brief_title>Tigecycline for Treatment of Rapidly Growing Mycobacteria</brief_title>
  <official_title>Use of Tigecycline for Treatment of Serious Infection Due to Rapidly Growing Mycobacteria (Especially M.Abscessus)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at Tyler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at Tyler</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients
      with rapidly growing mycobacterial disease (especially M.abscessus).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2002</start_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures</measure>
    <time_frame>Monthly while on treatment, then followup after therapy discontinuation will be evaluated monthly for one to two years or as deemed necessary</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological Cultures</measure>
    <time_frame>Monthly while on treatment, then followup after therapy discontinuation will be evaluated monthly for one to two years or as deemed necessary</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Mycobacterium Abscessus Lung Disease</condition>
  <condition>Rapidly Growing Mycobacterial Lung Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tigecycline</intervention_name>
    <description>Standard dose Tigecycline 50 mg daily IV; however, daily dose may be dependent on clinical factors such as age, weight and patient-specific health status</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Tygacil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive cultures for rapidly growing mycobacteria

          -  Patients who have drug resistant isolates or are intolerant of macrolides or have
             serious infections unresponsive to currently available drugs

          -  Adults and children 10 years of age and older

          -  Pretreatment isolate of M. avium complex available for MIC determination

          -  Available for followup appointments

        Exclusion Criteria:

          -  History of tetracycline allergy

          -  If a menstruating female, not pregnant and on adequate birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard J Wallace Jr., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at Tyler</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <lastchanged_date>January 14, 2008</lastchanged_date>
  <firstreceived_date>January 14, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Richard J. Wallace Jr. M.D.</name_title>
    <organization>The University of Texas Health Science Center at Tyler</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tigecycline</mesh_term>
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
